Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1992-1-30
pubmed:abstractText
Several LMWHs are currently available for commercial use. The development status of each of these products in the area of prophylaxis, therapeutics, and other indications is given in Table 4. Enoxaparin and Fraxiparin appear to be the most developed LMWHs in both the surgical and medical areas. Many well-designed clinical trials have been carried out for different clinical indications with both of these products. As demonstrated in both experimental and clinical settings, the prophylactic antithrombotic efficacy of Enoxaparin is distinct from other LMWHs. This agent has provided consistently impressive clinical results. However, at comparable dosages, other products have exhibited safety or efficacy profiles different from those of Enoxaparin. It is therefore justified to comment that the clinical performance of each LMWH is characteristic of only that particular agent. It can be stated that, provided proper developmental approaches, these agents will more than likely be the drugs of choice for the prophylaxis and therapy of thrombotic disorders. On the other hand, inadequate basic knowledge may result in the development of products with unknown safety or efficacy profiles whose introduction in clinical medicine may become related to problematic situations.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0094-6176
pubmed:author
pubmed:issnType
Print
pubmed:volume
17 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
319-28
pubmed:dateRevised
2006-3-7
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin).
pubmed:affiliation
Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153.
pubmed:publicationType
Journal Article, Review